A decade in the black: CLINUVEL banks tenth straight profit
CLINUVEL Pharmaceuticals has reported its tenth consecutive annual profit for the financial year ended 30 June 2026 (FY2026), reinforcing its financial independence as it self-finances an expansion into the United States. The result marks a decade of profitability since the company began commercial distribution of its lead therapy.
Revenues from ordinary activities eased 1% to $94.0M, while net profit after tax fell 6% to $33.9M. Cash reserves climbed 12% to $252.1M, and the Board declared a franked dividend of $0.05 per ordinary share.
The figures underscore CLINUVEL’s financial independence in a period that has been challenging for many life science companies. That balance sheet strength now anchors the company’s forward narrative, a self-financed push into North American operations and capital markets.
When big ASX news breaks, our subscribers know first
FY2026 financial results at a glance
The full-year comparison shows steady operations despite modest softening in revenue and profit. The standout remains the balance sheet, with cash reserves and net tangible asset backing both rising 12% year-on-year.
| Metric | 30 June 2026 | 30 June 2025 | Change YOY |
|---|---|---|---|
| Revenues | $94,024,000 | $95,018,000 | Down 1% |
| Revenues plus interest & other income | $101,153,000 | $105,300,000 | Down 4% |
| Expenses | $53,493,000 | $53,747,000 | Down 0.5% |
| Net profit before tax | $47,660,000 | $51,553,000 | Down 8% |
| Net profit after tax | $33,917,000 | $36,173,000 | Down 6% |
| Cash reserves | $252,055,000 | $224,106,000 | Up 12% |
| Basic EPS | $0.68 | $0.72 | Down 6% |
| NTA backing per share | $5.35 | $4.77 | Up 12% |
| Dividend per share | $0.05 | $0.05 | Stable |
The $4M (8%) decline in profit before tax to $47.7M was driven by the accounting treatment of recognising unrealised foreign currency losses on translation of the company’s US$ term deposit balances, rather than an operational shortfall. CLINUVEL noted record SCENESSE® treatment volumes and total revenues in excess of $100 million for the second consecutive year.
What drove the numbers
- Revenue growth in Europe offset marginal declines in U.S. sales, as some competitors offered free drug treatment to erythropoietic protoporphyria (EPP) patients.
- A shift by U.S. Specialty Centers from holding inventory to “just in time” supply of SCENESSE® from patient demand also affected U.S. volumes.
- Cash reserves would have reached $264M, an increase of 18%, had the company not prepaid $12.2M in FY2026 income tax.
- Net assets stood at $272.9M, with operating cash inflows of $36.9M underpinning the rise in reserves.
Peter Vaughan, Group Chief Financial Officer
“Our FY2026 results demonstrated the focused financial discipline we adopt across CLINUVEL… We delivered record SCENESSE® treatment volumes to EPP patients and total revenues in excess of $100 million for the second year in a row. Expenditures were tightly controlled to ensure every dollar deployed contributed to our core strategic objectives, such as our Phase III vitiligo program, thus building long-term shareholder value.”
The self-funding biotech model explained
CLINUVEL funds its research and development from product revenue, giving it financial independence to pursue its expansion strategy and continue investing through market cycles in key strategic areas.
That revenue is anchored by SCENESSE® (afamelanotide 16mg), described by the company as the world’s first systemic photoprotective drug for the prevention of phototoxicity in adult EPP patients. The therapy is approved for commercial distribution in Europe, the USA, Canada, Israel and Australia.
Over the past decade, CLINUVEL has achieved a revenue compound annual growth rate (CAGR) of 31%, outpacing an expenditure CAGR of 18%. Revenue growing faster than costs has allowed the company, in its own words, to “allocate capital based on opportunity rather than necessity” and to continue investing through market cycles in key strategic areas.
The company has also integrated critical operational functions in-house across the decade, including commercial distribution, regulatory compliance, product and clinical R&D, and communications, branding and marketing.
Dividend declared for shareholders
The CLINUVEL Board declared an annual franked dividend of $0.05 per ordinary share following the FY2026 results. The announcement describes this as the ninth consecutive annual dividend and the fifth fully franked.
The total dividend payment represents a return to shareholders of 9% of the FY2026 total free cash generated over the past year. Dividends are available to both Australian and overseas registered shareholders, including holders of CLINUVEL’s Level II American Depositary Shares.
Key dividend dates, per the announcement, are:
-
Ex-dividend date: 3 September 2025
-
Record date: 4 September 2025
-
Payment date: 18 September 2025
Building the U.S. expansion from a position of strength
The strengthened balance sheet directly supports the company’s forward strategy. CLINUVEL has emphasised expansion of its operations and capital markets presence in the United States and North America, self-financed from existing reserves.
The Phase III vitiligo program sits at the centre of the company’s research and development pipeline, part of a broader portfolio built around melanocortin peptides. The $252M cash buffer enables CLINUVEL to fund its diversification plans while providing protection against a volatile macroeconomic environment.
The Phase III vitiligo program received final EMA scientific advice following over 12 months of regulatory dialogue, with the pivotal CUV107 study targeting 300 adults and adolescents and scheduled to commence in the second half of 2026, comparing SCENESSE combined with narrowband UVB phototherapy against phototherapy alone.
The Nasdaq uplisting process, which involves CLINUVEL transitioning its ADR program from Level I to Level II under the proposed ticker CUVL, is a direct mechanism for deepening the company’s capital markets presence in the United States ahead of its anticipated vitiligo commercialisation window.
Peter Vaughan, Group Chief Financial Officer
“As CLINUVEL builds its operations and presence in the capital markets in the United States, we can do so from a position of strength.”
What’s next
-
Continued investment in the Phase III vitiligo program.
-
Expansion of operations and capital markets presence in North America.
-
An investor and analyst webinar hosted at 18:00 AEST on 27 August 2026 to review the FY2026 results.
Full detail on the financial results is available in the Appendix 4E Preliminary Final Report released to the Australian Securities Exchange.
Don’t Miss the Next Healthcare Profit Story
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000 subscribers are already getting the edge on market-moving announcements the moment they drop. Click the “Free Alerts” button to stay ahead of the next big healthcare result before the market moves.